The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
This year, the OCTF focused on preparing a white paper on oral cancer elimination in India and updating its annual consensus guidelines
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Revenue increased 11.4 per cent to Rs. 8,545 crore
Upgrades 2025 full-year CDMO sales and margin outlook
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Subscribe To Our Newsletter & Stay Updated
